UNC2025, a MERTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models

PURPOSE: MERTK tyrosine kinase is ectopically expressed in 30–50% of acute lymphoblastic leukemias (ALL) and over 80% of acute myeloid leukemias (AML) and is a potential therapeutic target. Here, we evaluated the utility of UNC2025, a MERTK tyrosine kinase inhibitor, for treatment of acute leukemia....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: DeRyckere, Deborah, Lee-Sherick, Alisa B., Huey, Madeline G., Hill, Amanda A., Tyner, Jeffrey W., Jacobsen, Kristen M., Page, Lauren S., Kirkpatrick, Gregory G., Eryildiz, Fatma, Montgomery, Stephanie A., Zhang, Weihe, Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Graham, Douglas K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354980/
https://ncbi.nlm.nih.gov/pubmed/27649555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1330
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak